Anti-Adalimumab Polyclonal Antibody

Adalimumab (Humira) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis. Adalimumab binds to the TNFα (tumor necrosis factor-alpha), and blocks its interaction with TNFα receptors, reducing the inflammatory response of autoimmune diseases.Antibodysystem Anti-Adalimumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Adalimumab.